"Social Media for Pharma Conference" in Princeton, NJ on May 24 & 25

The Advanced Learning Institute will be hosting a conference entitle Social Media for Pharma on May 24 & 25, 2010 at the Hyatt Hotel in Princeton, NJ. Presenters include representatives from AstraZeneca, Johnson & Johnson, Novartis, Sanofi-Aventis, NovoNordisk, Daiichi Sankyo, Lundbeck, Porter Novelli, the National Organization for Rare Diseases and many others. 

 

Topics to be covered include:

  • Developing a social media strategy that works for your organization
  • Update on regulatory guidance for social media
  • Managing on going regulatory challenges for social media
  • Building a business case and demonstrating ROI for social media platforms
  • Creating a stronger sense of community and brand recognition using social media
  • Monitoring customer feedback and satisfaction
  • Determine the right mix of social media for your organization
  • Latest innovations in social media
  • Using twitter to turn your employees into stakeholders into brand ambassadors

and much more!

An agenda for the meeting can be found here. Mention BioJobBlog or BioCrowd and get $200 off the registration fee. For more information please contact melissa@aliconferences.com

I hope to see you at the meeting…it ought to be a good one!!!!!!!!!!

Until next time..

Good Luck and Good Tweeting, Blogging, Podcasting etc etc!!!!!

 

AstraZeneca Offers New Details About Its Global Layoff Plans

Ed Silverman, who runs the Pharmalot blog,reported today that AstraZeneca provided more details about its plan to layoff 8,000 employees or 12% of its workforce by 2014. 

According to the post, the company will R&D programs in thrombosis; acid reflux; ovarian and bladder cancers; systemic scleroderma; schizophrenia, bipolar disorder, depression and anxiety; hepatitis C and vaccines (other than respiratory syncytial virus and influenza).

The company will shutter research facilities throughout the UK and Sweden and shed about 3,500 R&D jobs. About 550 jobs will be eliminated at AstraZeneca’s US headquarters in Wilmington, Delaware; adding to the massive numbers of unemployed pharmaceutical workers in the Pennsylvania, New Jersey and Delaware region. The company is also looking for a buyer for its Arrow Therapeutics business.

AstraZeneca joins a growing number of big pharma companies that are jettisoning internal R& D programs in favor of licensing and merger and acquisition deals to sure up drug discovery pipelines. The lack of innovation in small molecule drug discovery and the loss in 2011 of patent protection for some of the industry’s largest blockbuster drug franchises is forcing big pharma companies to eliminate or outsource most of their R&D functions and capabilities to cut costs.  

I wish I could say that things will get better. But, the shift in the business model that has guided big pharma for close to 100 years is likely to be a permanent one. Now is the time to begin to consider alternative career paths!

Until next time...

Good Luck and Good Job Hunting (“Go West young man/man!”)

Share/Bookmark